Summary of the Actions of the March Virtual House of Delegates

March 22-29, 2019
The House of Delegates

Ultimate authority over ASHP professional policies

One annual session consisting of 4 meetings: 2 meetings at the ASHP Summer Meeting and 2 virtual meetings in the spring and fall

Reviews policy proposals that have been approved by the Board of Directors

Most of these professional policy proposals are contained in reports from ASHP councils
ASHP Policy Process

Governance

House of Delegates

Board of Directors

Operations

ASHP Professional Policy

Councils

Other Appointed Groups

Component Groups

Members
To discontinue ASHP policy 9805, Medication Misadventures, which reads:

To affirm that pharmacists must assume a leadership role in preventing, investigating, and eliminating medication misadventures across the continuum of care.
CPhP: Telepharmacy

Source: Council on Pharmacy Practice

To discontinue ASHP policy 9920, Telepharmacy, which reads:

To foster among health-system pharmacists and leaders of the telecommunications industry a common vision for the integration of telecommunication technology into the delivery of pharmaceutical care.
CPhP: Pharmaceutical Counterfeiting

Source: Council on Pharmacy Practice
To discontinue ASHP policy 0401, Pharmaceutical Counterfeiting, which reads:

To foster increased pharmacist and public awareness of drug product counterfeiting; further,

To encourage pharmacists to purchase and handle medications in ways that enhance the transparency and integrity of the drug product supply chain; further,

To encourage pharmacists to identify instances of drug product counterfeiting and to respond by assisting the patient in receiving appropriate treatment and monitoring, documenting patient outcomes, and notifying the patient, prescriber, and appropriate state and federal regulatory bodies (e.g., the Food and Drug Administration’s MedWatch system); further,

To provide consumers and health professionals with information on how to avoid counterfeit drug products and how to recognize, respond to, and report encounters with suspicious drug products; further,

To foster research and education on the extent, methods, and impact of drug product counterfeiting and on strategies for preventing and responding to drug product counterfeiting.
CPhP: Pharmacist Validation of Information Related to Medications

Source: Council on Pharmacy Practice
To discontinue ASHP policy 9921, Pharmacist Validation of Information Related to Medications, which reads as follows:

To support consultation with a pharmacist as a primary means for consumers to validate publicly available information related to medications.
Questions or Suggestions?

Feel free to contact:

Casey White, Chair, ASHP House of Delegates: hodchair@ashp.org

ASHP: https://www.ashp.org/Pharmacy-Practice/Policy-Positions-and-Guidelines/Participate-in-Guidance-Development